Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis. In addition, the company develops RLF-TD011, a hypochlorous acid solution for epidermolysis bullosa. Further, it is developing RLF-OD32, a next-generation liquid sapropterin formulation for phenylketonuria. Relief Therapeutics Holding SA was founded in 2013 and is based in Geneva, Switzerland. Show more
Location: Avenue de Secheron 15, Geneva, 1202, Switzerland | Website: https://www.relieftherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
35.84M
52 Wk Range
$1.10 - $7.66
Previous Close
$2.85
Open
$2.82
Volume
2,545
Day Range
$2.60 - $2.88
Enterprise Value
22.18M
Cash
15.08M
Avg Qtr Burn
-729K
Insider Ownership
1.00%
Institutional Own.
23.11%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RLF-TD011 (APR-TD011) Details Epidermolysis bullosa | Phase 1 Update |